Authors:
L.V. Stakhovskaya1, E.A. Tyutyumova2*, A.I. Fedin2
1-way research institute of cerebrovascular pathology and stroke of the Federal State Budgetary Institution “Russian National
Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia; 2
FSBEI in Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia
The results of a series of domestic clinical trials are given to study the effectiveness and safety of the drug Mexidol in patients with cerebrovascular disorders, in particular with ischemic stroke (AI). It is emphasized that the use of Mexidol is associated with a more complete and rapid regression of focal neurological deficiency. Good tolerance of treatment with Mexidol and the absence of significant undesirable side effects are noted. It is recommended to use the drug in forms for enteric and parenteral use in patients with AI.
Key words: ischemic stroke, treatment, Mexidol.